Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ph13110377 http://scihub22266oqcxt.onion/10.3390/ph13110377 33182811!7696195!33182811     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33182811&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Pharmaceuticals+(Basel) 2020 ; 13 (11): ? Nephropedia Template TP {{tp|p=33182811|t=2020. Role of 2- (18)F FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review |pdf=|usr=}}{{33182811}} gab.com Text Role of 2- (18)F FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review JO: Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33182811 #FOAvip Some recent studies evaluated the role of fluorine-18 fluorodeoxyglucose (2-[(18)F]FDG) as a radiopharmaceutical for positron emission tomography/computed tomography (PET/CT) imaging in patients with Coronavirus Disease (COVID-19). This article aims to perform a systematic review in this setting. A comprehensive computer literature search in PubMed/MEDLINE and Cochrane library databases regarding the role of 2-[(18)F]FDG PET/CT in patients with COVID-19 was carried out. This combination of key words was used: (A) "PET" OR "positron emission tomography" AND (B) "COVID" OR "SARS". Only pertinent original articles were selected; case reports and very small case series were excluded. We have selected 11 original studies of 2-[(18)F]FDG PET/CT in patients with COVID-19. Evidence-based data showed first preliminary applications of this diagnostic tool in this clinical setting, with particular regard to the incidental detection of interstitial pneumonia suspected for COVID-19. To date, according to evidence-based data, 2-[(18)F]FDG PET/CT cannot substitute or integrate high-resolution CT to diagnose suspicious COVID-19 or for disease monitoring, but it can only be useful to incidentally detect suspicious COVID-19 lesions in patients performing this imaging method for standard oncological and non-oncological indications. Published data about the possible role of 2-[(18)F]FDG PET/CT in patients with COVID-19 are increasing, but larger studies are warranted. Twit Text FOAVip Role of 2- (18)F FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review ????Pharmaceuticals (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=33182811 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33182811 #FOAvip English Wikipedia <ref>{{Cite pmid|33182811}}</ref> Role of 2- (18)F FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review #MMPMID33182811 Annunziata S; Delgado Bolton RC; Kamani CH; Prior JO; Albano D; Bertagna F; Treglia G Pharmaceuticals (Basel) 2020[Nov]; 13 (11): ? PMID33182811show ga Some recent studies evaluated the role of fluorine-18 fluorodeoxyglucose (2-[(18)F]FDG) as a radiopharmaceutical for positron emission tomography/computed tomography (PET/CT) imaging in patients with Coronavirus Disease (COVID-19). This article aims to perform a systematic review in this setting. A comprehensive computer literature search in PubMed/MEDLINE and Cochrane library databases regarding the role of 2-[(18)F]FDG PET/CT in patients with COVID-19 was carried out. This combination of key words was used: (A) "PET" OR "positron emission tomography" AND (B) "COVID" OR "SARS". Only pertinent original articles were selected; case reports and very small case series were excluded. We have selected 11 original studies of 2-[(18)F]FDG PET/CT in patients with COVID-19. Evidence-based data showed first preliminary applications of this diagnostic tool in this clinical setting, with particular regard to the incidental detection of interstitial pneumonia suspected for COVID-19. To date, according to evidence-based data, 2-[(18)F]FDG PET/CT cannot substitute or integrate high-resolution CT to diagnose suspicious COVID-19 or for disease monitoring, but it can only be useful to incidentally detect suspicious COVID-19 lesions in patients performing this imaging method for standard oncological and non-oncological indications. Published data about the possible role of 2-[(18)F]FDG PET/CT in patients with COVID-19 are increasing, but larger studies are warranted. ?Role of 2- (18)F FDG as a Radiopharmaceutical for PET/CT in Patients w(epmc).pdf DeepDyve Pubget Overpricing